Peter Greenleaf - Mar 2, 2023 Form 4 Insider Report for Aurinia Pharmaceuticals Inc. (AUPH)

Signature
/s/ Peter S. Greenleaf
Stock symbol
AUPH
Transactions as of
Mar 2, 2023
Transactions value $
-$292,785
Form type
4
Date filed
3/6/2023, 03:27 PM
Previous filing
May 26, 2022
Next filing
Feb 22, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AUPH Common Stock Award +667K +191.61% 1.02M Mar 2, 2023 Direct F1, F2, F3, F4
transaction AUPH Common Stock Sale -$293K -32.8K -3.22% $8.94 983K Mar 2, 2023 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents grant of Restricted Stock Units (RSUs) payable solely in common stock of the Issuer that vest in three (3) equal annual installments on the first, second and third anniversary of the grant date.
F2 Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F3 Includes shares of common stock acquired by the reporting person pursuant to the Issuer's 2021 Employee Share Purchase Plan as follows: 1,221 shares of common stock were acquired on May 31, 2022 and 1,883 shares of common stock were acquired on November 30, 2022.
F4 The reporting person has reported prior awards of restricted stock units in Table II of Form 4. The total reported in Column 5 includes the 667,407 newly awarded RSUs, 312,240 RSUs previously reported in Table II, which vests in three (3) equal annual installments beginning March 2, 2022 (Prior RSUs), and 32,967 shares of common stock. On March 2, 2023, 104,080 of Prior RSUs vested and 208,160 of Prior RSUs remained unvested.
F5 Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of RSUs.